ReviewClinical microbiology reviews2020
Coronavirus Disease 2019-COVID-19.
Review in Clinical microbiology reviews, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 552 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
552 citing papers in PubMed, 4 syntheses or guidelines pooled it, 1,850 citations in OpenAlex.
- The efficacy and effectiveness of COVID-19 vaccines in Iran: a systematic review and meta-analysis.BMC infectious diseases · 2025Pooled it
- Mapping the intersection of sudden cardiac death and COVID-19: a comprehensive bibliometric analysis (2020-2024).Frontiers in cardiovascular medicine · 2024Pooled it
- Global prevalence of COVID-19-induced acute respiratory distress syndrome: systematic review and meta-analysis.Systematic reviews · 2023Pooled it
- Effect of anti-inflammatory drugs on the storm of inflammatory factors in respiratory tract infection caused by SARS-CoV-2: an updated meta-analysis.Frontiers in public health · 2023Pooled it
- Multiplexed detection of febrile infections using CARMEN.Nature communications · 2025Trial
- Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial.Nutrients · 2023Trial
- Risk Factors of COVID-19 Associated Mucormycosis (CAM) in Iranian Patients: A Single-Center Retrospective Study.Mycopathologia · 2022Trial
- Pulmonary and Functional Rehabilitation Improves Functional Capacity, Pulmonary Function and Respiratory Muscle Strength in Post COVID-19 Patients: Pilot Clinical Trial.International journal of environmental research and public health · 2022Trial
- Surface-Enhanced Raman Spectroscopy for Viral Diagnostics: Principles, Strategies, Clinical Challenges, and Future Directions.Chemical reviews · 2026Review
- Economic burden of COVID-19 on hospitalized patients: a cross-sectional study from Semnan, Iran.BMC health services research · 2026Article
- The seven human coronavirus main proteases exhibit differential modulation of NF-κB suppression via TAB1 cleavage.Communications biology · 2026Article
- Emerging Trends in Artificial Intelligence-Integrated Biochip Technologies for Biomedical Applications.Micromachines · 2026Review
- Efficacy of Mouthwashes Delivered via Dental Unit Waterlines in Reducing Aerosolized Surrogate SARS-CoV-2.Medical science monitor : international medical journal of experimental and clinical research · 2026Article
- COVID-19 vaccine acceptability and determinants of hesitancy among adults in Lagos, Nigeria.BMC public health · 2026Article
- Evaluation of D-Dimer, P-Selectin, and miR-17-5p Expression in ICU and Non-ICU COVID-19 Patients: A Cross-sectional Study.Biochemical genetics · 2026Article
- Article
- SARS-CoV-2 infection in dogs, dog owners, dog breeders, and veterinarians in the Ashanti and Greater Accra regions of Ghana-zoonotic implications.Frontiers in veterinary science · 2026Article
- COVID-19-Related Hematological Abnormalities Among Adults; A Cross-Sectional Study in a Resource-Limited Setting.Immunity, inflammation and disease · 2026Article
- Article
- Disease outbreak preparedness: a baseline assessment of infection prevention and control practice in healthcare facilities in Lagos, Nigeria.BMJ public health · 2026Article
492 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 4 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SUMMARYIn recent decades, several new diseases have emerged in different geographical areas, with pathogens including Ebola virus, Zika virus, Nipah virus, and coronaviruses (CoVs). Recently, a new type of viral infection emerged in Wuhan City, China, and initial genomic sequencing data of this virus do not match with previously sequenced CoVs, suggesting a novel CoV strain (2019-nCoV), which has now been termed severe acute respiratory syndrome CoV-2 (SARS-CoV-2). Although coronavirus disease 2019 (COVID-19) is suspected to originate from an animal host (zoonotic origin) followed by human-to-human transmission, the possibility of other routes should not be ruled out. Compared to diseases caused by previously known human CoVs, COVID-19 shows less severe pathogenesis but higher transmission competence, as is evident from the continuously increasing number of confirmed cases globally. Compared to other emerging viruses, such as Ebola virus, avian H7N9, SARS-CoV, and Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV-2 has shown relatively low pathogenicity and moderate transmissibility. Codon usage studies suggest that this novel virus has been transferred from an animal source, such as bats. Early diagnosis by real-time PCR and next-generation sequencing has facilitated the identification of the pathogen at an early stage. Since no antiviral drug or vaccine exists to treat or prevent SARS-CoV-2, potential therapeutic strategies that are currently being evaluated predominantly stem from previous experience with treating SARS-CoV, MERS-CoV, and other emerging viral diseases. In this review, we address epidemiological, diagnostic, clinical, and therapeutic aspects, including perspectives of vaccines and preventive measures that have already been globally recommended to counter this pandemic virus.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.